Valuation : Xencor, Inc.

Market Cap 2.08B 1.79B 1.68B 1.53B 2.88B 197B 2.9B 19.91B 7.75B 100B 7.79B 7.62B 332B P/E 2026 *
-9.17x
P/E 2027 * -8.76x
Enterprise Value 1.64B 1.42B 1.33B 1.21B 2.28B 156B 2.3B 15.75B 6.13B 79.28B 6.17B 6.03B 263B EV / Sales 2026 *
11.4x
EV / Sales 2027 * 16.5x
Free-Float
98.78%
Yield 2026 *
-
Yield 2027 * -
1 day+2.37%
1 week-4.74%
Current month+2.37%
1 month+38.10%
3 months+136.53%
6 months+118.56%
Current year+82.30%
1 week 25.8
Extreme 25.805
28.97
1 month 19.07
Extreme 19.07
30.61
Current year 10.38
Extreme 10.375
30.61
1 year 7.91
Extreme 7.91
30.61
3 years 6.92
Extreme 6.92
30.61
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 01/02/2005
Director of Finance/CFO 48 09/04/2024
Chief Tech/Sci/R&D Officer 61 01/10/2006
Director TitleAgeSince
Director/Board Member 55 01/08/1997
Director/Board Member 58 25/07/2014
Director/Board Member 72 18/03/2015
Date Insider Type Main position Quantity % Market Cap. Importance
16/6/26 Free

Director

30,906 0.0417%
10/4/26 Sell

Chief Financial Officer

3,499 0.0048%
5/3/26 Sell

Chief Technology Officer

6,620 0.0090%
Change 5-day change 1-year change 3-year change Capi.($)
+2.37%-4.74%+243.30%+24.43% 2.08B
-0.25%-4.10%+38.38%+92.61% 68.21B
+1.21%+0.80%+46.29%+85.32% 64.25B
-0.25%-1.92%-10.72%+436.70% 26.54B
+0.33%-10.61%+1.95%-16.27% 25.61B
+1.18%-2.23%+30.87%-19.04% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.04%-5.74%-1.60%+531.81% 14.93B
+4.12%+0.30%+52.03%+150.18% 14.1B
-0.24%+5.18%+23.04%+190.97% 12.45B
Average +0.25%-4.01%+64.96%+185.17% 26.52B
Weighted average by Cap. +0.17%-3.24%+42.79%+156.51%

Financials

2026 *2027 *
Net sales 144M 124M 117M 106M 200M 13.66B 201M 1.38B 537M 6.95B 540M 529M 23.04B 126M 108M 102M 92.86M 175M 11.92B 176M 1.2B 469M 6.06B 472M 461M 20.11B
Net income -238M -206M -193M -176M -331M -22.63B -333M -2.29B -890M -11.51B -895M -876M -38.17B -280M -241M -227M -207M -389M -26.53B -391M -2.68B -1.04B -13.5B -1.05B -1.03B -44.75B
Net Debt -433M -374M -351M -320M -602M -41.09B -605M -4.15B -1.62B -20.9B -1.63B -1.59B -69.31B -
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
01/09/26 US$27.91 +2.37% 1,475,981
31/08/26 US$27.27 +4.62% 1,808,116
28/08/26 US$26.06 -9.76% 2,051,639
27/08/26 US$28.88 +1.55% 1,553,695
26/08/26 US$28.44 -2.94% 2,121,833
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
27.91USD
Average target price
29.50USD
Spread / Average Target
+5.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XNCR Stock